Professor, Dermatology
School of Medicine

Director of Student Education, Dermatology
School of Medicine

2024 | Best Doctors in America
2023 | Best Doctors in America
2022 | Best Doctors in America
2021 | Best Doctors in America
2020 | Best Doctors in America

JOURNAL PUBLICATIONS
1. Linden KG, Benisek WF. (1986) Amino Acid Sequence of a ?5-3-Oxosteroid Isomerase from Pseudomonas putida Biotype B. J Biol Chem. 261(41), 6454-6460.
2. Hasan T, Chen N, Anderson T, Deak MR, Linden K, Granstein R, Zurawski VR Jr, Flotte T. (1989) Immunologic Targeting of Cancer Cells. Proceedings of the SPIE, Fundamentals of photodynamic Therapy, Editor Thomas J. Doughtery. Los Angeles. Volume 1065.
3. Linden KG, Liao JC, Jay DG. (1992) Spatial Specificity of Chromophore Assisted Laser Inactivation of Protein Function. Biophysical Journal. 61(4), 956-962.
4. Jeffes III EWB, Lee GC, Said S, Sabahi M, McCullough JL, Herrod R, Alzona CP, Linden KG, Soundararajan D, Edwards S, Weinstein GD. (1995) Elevated Numbers of Proliferating Mononuclear Cells in the Peripheral Blood of Psoriatic Patients Correlate with Disease Severity. Journal of Investigative Dermatology. 105(6); 733-738.
5. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, Shupack J, Weinstein G. (1998) Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. Journal of the American Academy of Dermatology. 39(3): 464-75.
6. Linden KG, Weinstein GD. (1999) Use of methotrexate in psoriasis. Dermatologic Therapy. 11:52-59.
7. Linden KG, Weinstein GD. (1999) Psoriasis: current perspectives with an emphasis on treatment. Am J Med. 107(6): 595-605.
8. Hui JI, Linden KG, Barr RJ. (2002) Desmoplastic Malignant Melanoma of the Lip. Journal of the American Academy of Dermatology. 47(6): 863-8.
9. Barr RJ, Linden KG, Rubinstein G, cantos KA. (2003) Analysis of heterogeneity of atypia within melanocytic nevi. Archives in Dermatology. 139(3): 289-292.
10. Linden KG, Carpenter PM, McLaren CE, Barr RJ, Hite P, Sun JD, Li KT, Viner JL, Meyskens GL. Chemoprevention of Nonmelanoma Skin Cancer: Experience with a Polyphenol from Green Tea. Recent Results in Cancer Research. 2003. 163: 165-171.
11. Gottlieb AB, Kang S, Linden KG, Lebwohl M, Menter A, Abdulghani AA, Goldfarb M, Chieffo N, Totoritis MC. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol. 2003. 163: 165-171.
12. Linden KG. Screening and early detection of skin cancer. Curr Oncol Rep. 2004 Nov;6(6): 491-6.
13. Carpenter PM, Linden KG, McLaren CE, Li KT, Arain S, Barr RJ, Hite P, Sun JD, Meyskens FL. Nuclear morphometry and molecular biomarker studies of actinic keratoses, sun-damaged, and non sun-damages skin. Cancer Epidemiology, Biomarkers, and Prevention. 2004 Dec;13(12): 1996-2002.
14. Cassarino DS, Linden KG, Barr RJ. Cutaneous Keratocyst Arising Independently of the Nevoid Basal Cell Carcinoma Syndrome. American Journal of Dermatopathology. 2005 Apr;27(2): 177-8.
15. Sun JD, Linden KG. Netherton Syndrome: A case report and review of literature. International Journal of Dermatology. 2006 Jun;45(6): 693-7.
16. Kappel ST, Wu JJ, Hillman JD, Linden KG. Histopathologic findings of disseminated coccidioidomycosis with hyphae. Arch Dermatol. 2007 Apr;143(4):548-9.
17. Ortiz AE, Wu JJ, Linden KG. Clear Margins after the Use of Imatinib Mesylate prior to Resection of Extensive Dermatofibrosarcoma Protuberans. Dermatol Surg. 2008 May 28.
18. Breneman D, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008 Jun;58(6):990-9. Epub 2008 Mar 21.
19. Phillips TJ, et al. Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women. J Am Acad Dermatol. 2008 Sep;59(3):397-404.e3. Epub 2008 Jul 14.
20. Paller AS, et al. Tacrolimus Ointment Study Group. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics. 2008 Dec;122(6):e1210-8. Epub 2008 Nov 17.
21. Fife DJ, Wu JJ, Behnam SE, Linden KG. Sunitinib-induced hand-foot syndrome: a new, distinct form. Clin Exp Dermatol. 2010 Mar;35(2):200-1.
22. Bertoni JM, et al. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol. 2010 Mar;97(3)347-52.
23. Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010 Dec 15;102(42):1835-44.
24. Kamell JM, Rietkerk W, Lam K, Phillips JM, Wu JJ, McCullough JL, Linden KG, Osann K. Medical students educate teens about skin cancer: what have we learned? J Cancer Educ. 2011 Mar;26(1):153-5.
25. Linden KG, Leachman SA, Zager JS, Jakowatz JG, Viner JL, McLaren CE, Barr RJ, Carpenter PM, Chen WP, Elmets CA, Tangrea JA, Lim SJ, Cochran AJ, Meyskens FL Jr. A Randmized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology. Cancer Prev Res (Phila). 2014 May;7(5):496-504.
26. Chapman LW, Korta DZ, Lee PK, Linden KG. Awareness of Surgical Smoke Risks and Assessment of Safety Practices During Electrosurgery Among US Dermatology Residents. JAMA Dermatol. 2017 May 1;153(5):467-468. PubMed PMID: 28249072.
27. Korta DZ, Chapman LW, Linden KG. Splash Safety During Dermatologic Procedures Among US Dermatology Residents. Dermatol Surg. 2017 Jul;43(7):934-939. PubMed PMID: 28346255.
28. Zikry J, Korta DZ, Chapman LW, Linden KG. Melanoma arising in an ovarian cystic teratoma: a systematic review of presentation, treatment, and outcomes. Arch Gynecol Obstet. 2017 Sep;296(3):397-404. PubMed PMID: 28643027.
29. Amber KT, Valdebran M, Lu Y, DeFeraudy S, Linden KG. Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma. J Dtsch Dermatol Ges. 2018 Feb;16(2):196-198. PubMed PMID: 29389067.
30. Abrouk M, Song JW, Linden KG. A recalcitrant case of toxic epidermal necrolysis. Cutis. 2018 Mar;101(2):E8-E10. PubMed PMID; 29718031.
31. Linden KG. Commentary: Sunscreen sun protection factor (SPF): Is higher better? J Am Acad Dermatol. 2018 May;78(5):911-912. PubMed PMID: 29548519.
32. Hosking AM, Makdisi J, Ortenzio D, DeFeraudy S, Smith J, Linden K. Diffuse cutaneous mastocytosis: Case report and literature review. Pediatr Dermatol. 2018 Nov;35(6):e349-e352. PubMed PMID: 30187958.
33. Hosking AM, Coakley BJ, Chang D, Talebi-Liasi F, Lish S, Lee SW, Zong AM, Moore I, Browning J, Jacques SL, Krueger JG, Kelly KM, Linden KG, Gareau DS. Hyperspectral imaging in automated digital dermoscopy screening for melanoma. Lasers Surg Med. 2019 Mar;51(3):214-222. doi: 10.1002/lsm.23055. Epub 2019 Jan. PMID: 30653684; PMCID: PMC6519836.
34. Shwe S, Kraus CN, Linden KG, Rojek NW. Erythema multiforme in a child with Kawasaki disease. JAAD Case Rep. 2019 Apr 6;5(4):386-388. doi: 10.1016/j/jdcr.2019.02.013. PMID: 31008176; PMCID: PMC6454123.
35. Sharma AN, Dobry AS, Linden K. Hyperpigmentation Due to Cyclosporine Therapy. Cureus. 2019 Feb 14;11(2):e4072. doi: 10.7759/cureus.4072. PubMed PMID: 31019850; PMCID: PMC6464983.
36. Choid FD, Kraus CN, Elsensohn AN, Carley SK, Lehmer LM, Nguyen RT, Linden KG, Shiu J. Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. J Am Acad Dermatol. 2020 Feb;82(2):440-459. doi: 10.1016/j/jaad.2019.05.077. Epub 2019 Jun 1. PMID: 31163235.
37. Hou Z, Heckel C, Linden K, Rotunda AM. A diagnostically challenging spindle cell carcinoma on the neck: Treatment with Moha micrographic surgery and clinical course. JAAD Case Rep. 2020 Mar 25;6(4):305-307. doi: 10.1016/j.jdcr.2020.01.026. PMID: 32258305; PMCID: PMC7109367.
38. Lentsch G, Valdebran M, Saknite I, Smith J, Linden KG, Konig K, Barr RJ, Harris RM, Tromberg BJ, Ganesan AK, Zachary CB, Kelly KM, Balu M. Non-invasive optical biopsy by multiphoton microscopy identifies the live morphology of common melanocytic nevi. Pigment Cell Melanoma Res. 2020 Jun 2. doi: 10.1111/pcmr.12902. Epub ahead of print. PMID: 32485062.
39. Brody G, Yale K, Nguyen A, Doan L, Linden K. A retrospective, cross-sectional study characterizing site-specific and laterality patterns of keratoacanthomas. Int J Dermatol. 2020 Jun 19. doi: 10.1111/ijd.15068. Epub ahead of print. PMID: 32686082.
40. Kim DJ, Truong SV, Paik A, Kraus C, Harris RM, Barr RJ, Linden KG, Smith J. A case of acanthosis nigricans-like mycosis fungoides. JAAD Case Rep. 2021 Sep 8;16:144-148. doi: 10.1016/j.jdcr.2021.08.032. eCollection 2021 Oct. No abstract available. PubMed PMID: 34621939; PMCID: PMC8484728.
41. Shwe S, Yamamoto M, Linden KG, Lee BA. Tumoral Melanosis and Separate Granulomatous Inflammation Due to Talimogene Laherparepvec. Am J Dermatopathol. 2022 Jul 1;44(7):541-543. doi: 10.1097/DAD.0000000000002174. Epub 2022 Mar 1. No abstract available. PubMed PMID: 35234191.
42. Stetkevich SA, Urso B, Saeed L, Hosking AM, Lee BA, Grando SA, Linden KG. Yellow urticaria: a rare phenomenon. Int J Dermatol. 2023 Apr;62(4):e225-e226. Doi: 10.1111/ijd.16093. Epub 2022 Feb 21. No abstract available. PubMed PMID: 35187655.
43. Li Y, Moon DJ, Linden KG. Harlequin sign associated with Horner syndrome secondary to an 11 cm left upper lung lobe adenocarcinoma. JAAD Case Rep. 2023 Nov 3:43:83-86 PMID: 38223366.
44. Messele F, Horton L, Sharm AN, Min MS, Rojek NW, Linden KG. Relapsing toxic epidermal necrolysis following COVID-19. JAAD Case Rep. 2024 Jul 31;53:23-26. PMID: 39430626.
44. Aguero R, Buchanan KL, Navarrete-Dechent C, Marghoob AA, Stein JA, Landy MS, Leachman SA, Linden KG, Garcet S, Krueger JG, Gareau DS. The Impact of Melanoma Imaging Biomarker Cues on Detection Sensitivity and Specificity in Melanoma versus Clinically Atypical Nevi. Cancers (Basel). 2024 Sep 4;16(17):3077. PMID: 39272935.

5/1998-5/2003. Principal Investigator and Medical Director, NCI Clinical Trial. Study Title: A Phase II Clinical Trial of Topical Polyphenon E in Subjects with Actinic Keratoses. $397,000 + additional amount

3/1999-2/2002. Co-Investigator with Professor Ronald Barr (PI) and co-workers. Study Title: Analysis of heterogeneity of atypia within melanocytic nevi

10/1999-1/2002. Co-Investigator, UCI Beckman Laser Institute Clinical Trial (J. Stuart Nelson, PI). Study Title: Optical Biopsy of Human Skin

9/2000-6/2002. Principal Investigator, Investigator Initiated Clinical Research Study. Study Title: Anatomic Location of Malignant Melanoma

9/2000-2/2006. Lead Investigator, NCI-Searle Clinical Trial. Study Title: Phase II/III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Celecoxib in Subjects with Actinic Keratoses. $239,986

8/2001-10/2005. Key Co-Investigator (Gultekin Gulsen, PI), NCI sponsored research study. Study Title: Characterization of Melanoma by Polarization Sensitive Optical Coherence Tomography. $368,875.

2/2004-2014. Principal Investigator, Protocol Lead Investigator, & Protocol Chair, NCI sponsored multicenter clinical trial on the chemoprevention of melanoma. $900,000.

2014-Present. Principal Investigator, Rockefeller University sponsored Multicenter Clinical Trial. Study Title: Multi-Center Evaluation of Oncogenesis via Spectral Analysis with the Melanoma Advances Imaging Dermatoscope (mAID).

4/1999-2/2000. Principal Investigator, Genetics Institute Psoriasis Clinical Trial. Study Title: A Phase I/II Randomized, Double-Masked, Placebo-Controlled Study of Recombinant Human Interleukin Eleven in the Treatment of Active Psoriasis. $82,466.

12/1999-4/2001. Principal Investigator, IDEC sponsored Clinical Trial. Study Title: Phase I/II Multi-Dose, Multi-Schedule, Safety, Tolerability, and Dose-Finding Study of IDEC-114 in Patients with Moderate to Severe Plaque Psoriasis. $97,000.

10/2000-5/2002. Principal Investigator, Parke-Davise sponsored clinical trial. Study Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study Assessing the Effects of Norethindrone Acetate and Ethinyl Estradiol in the Improvement of Moderate to Severe Age-Related Skin Changes in Postmenopausal Women. $60,697.

2/2001-7/2002. Principal Investigator, IDEC sponsored Clinical Trial. Study Title: A Phase II Randomized, Double-Blind, Placebo-Controlled, Multi-Dose, Dose and Schedule Finding, Safety and Efficacy Study of IDEC-114 in Patients with Moderate to Severe Plaque Psoriasis. $92,390.

3/2001-7/2002. Principal Investigator, Bertek sponsored Clinical Trial. Study Title: Evaluation of the Safety and Efficacy of tretinoin Lotion 0.25% in the Topical Treatment of Actinic Keratoses of the Face and Scalp. $66,375.

8/2002-5/2003. Principal Investigator, Fujisawa sponsored Clinical Trial. Study Title: A Phase 2, Randomized, Double-Blind Study to Evaluation the Dosing Concentration and Application Frequency of Tacrolimus gel in the Treatment of Mild to Moderate Psoriasis in Pediatric and Adult Patients. $90,000.

2/2007-7/2006. Principal Investigator, Dermtech sponsored Clinical Trial. Study Title: Early Diagnosis of Melanoma with Non-Invasive Sampling and DNA Microarrays.

12/2006-12/2008. Co-Investigator, Galderma sponsored Clinical Trial. Study Title: A multi-center, randomized, double-blind, parallel-group study to demonstrate the efficacy and safety of Adapalene/Benzoyl Peroxide topical gel compared with Adapalene topical gel, 0.1% Benzoyl Peroxide topical gel, 2.5% and topical gel vehicle subjects with Acne Vulgaris.

8/2008-9/2009. Principal Investigator, Symbio LLC/TEVA sponsored Clinical Trials. Study Title: A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Comparing Imiquimod Cream, 5% to Aldara (Imiquimod) Cream, 5% and Both Active Treatments to a Vehicle Control n the Treatment of Actinic Keratosis of the Face or Scalp. $38,000.

2012-2017. Principal Investigator, Genentech sponsored Clinical Trial. Study Title: A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients – “RegiSONIC.”

American Association for the Advancement of Science

American Chemical Society

American Academy of Dermatology

Southwest Oncology Group

Orange County Dermatology Society

American Society for Mohs Surgery

Link to this profile
https://faculty.uci.edu/profile/?facultyId=7284

Last updated
01/16/2025